Vistogard® is being distributed by BTG Pharmaceuticals as of July 1, 2023. For more details please click here.

The first and only treatment for early-onset, severe or serious 5-FU toxicity 1, 2, 19

Vistogard® (uridine triacetate) oral granules—a documented safety profile 1, 2, 19

Treat with confidence

Adverse reactions occurring in >2% of patients (N=135)
Adverse Reactions Number of Patients Percent of Patients
Vomiting 13 10%
Nausea 7 5%
Diarrhea 4 3%
  • No contraindications, warnings, precautions, or cytochrome P450 drug–drug interactions4
  • May be taken without regard to meals4
  • Pharmacokinetics were not significantly affected by gender or age (in patients aged 20 to 83 years)4
  • Geriatric patients: Of the 135 patients in clinical studies with Vistogard®, 30% were ≥65, including 11% ≥75
  • One patient receiving Vistogard® had Grade 3 nausea and vomiting4
  • Vistogard® was discontinued for adverse reactions in 2 (1.4%) patients4


VISTOGARD is indicated for the emergency treatment of adult and pediatric patients:

  • following a fluorouracil or capecitabine overdose regardless of the presence of symptoms, or
  • who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration.

Limitations of use

  • VISTOGARD is not recommended for the non–emergent treatment of adverse reactions associated with fluorouracil or capecitabine because it may diminish the efficacy of these drugs.
  • The safety and efficacy of VISTOGARD initiated more than 96 hours following the end of fluorouracil or capecitabine administration have not been established.

You are now leaving the patient site.

The section you selected contains information intended for U.S. healthcare professionals only.
Please certify that you are a U.S. healthcare professional by clicking the link below.